Philadelphia- ACI Clinical has surpassed a new milestone of 50,000 adjudicated endpoints during the first quarter of 2017.
The specialty adjudication company is pioneering adjudication practices beyond the traditional large cardiovascular outcome trials into a wide breadth of medical specialties with emerging needs for safety and efficacy endpoint evaluation. These include oncology adjudication, medical device adjudication, neurology, immunology, gastroenterology, urology, infectious disease, endocrinology, pulmonary, and many more. ACI Clinical’s industry-leading model permits cost-efficient endpoint adjudication for programs with large or small numbers of events. ACI’s adjudication services are continually top-rated by a global network of over 500 academic medical experts, sponsor companies, and site personnel for ease of use, value and effectiveness.
Adjudicated endpoints can provide critical support to regulatory submissions, commercial labeling and reimbursement decisions by reducing variation in event reporting and serving as a quality check on clinical trial data. ACI’s executive leadership continues to work with multi-stakeholder groups to develop new ways to drive efficiencies in adjudication, safety assessment and risk-based data monitoring. ACI’s processes are based on published industry best practices, thorough documentation, and their proprietary adjudication platform (AIMS®) that optimizes workflows for source document submission and process quality control prior to independent adjudicator review and voting.
About ACI Clinical
ACI Clinical is a leading provider of Independent Endpoint Adjudication and Data Monitoring Committees for clinical trials. The company offers the largest committee-dedicated staff in the industry, its own global network of more than 500 expert medical and safety physicians as a source of committee members, and proprietary technologies designed to support efficient committee interactions. Company leadership is actively involved in public-private thought leadership efforts to improve the quality and effectiveness of clinical trials, and currently participate in projects with the Cardiac Safety Research Consortium (CSRC), the Clinical Trials Transformation Initiative (CTTI), the Clinical Data Interchange Standards Consortium (CDISC), and the American Statistical Association (ASA).
For more information, contact:
VP, Client Services
Phone: +1 484-429-7200